Oncotype DX sounds advanced — but it only measures 21 genes.
In this episode of OutSmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains the limitations of Oncotype DX and how precision oncology gives patients a complete picture of their breast cancer biology. Instead of guessing with a one-size-fits-all approach, Dr. Prato shows how combining DNA sequencing, RNA transcriptomics, and immune profiling creates a full “GPS” view of your cancer to guide smarter, safer, and more effective treatment.
He also compares Oncotype DX with the POETIC study, explaining why both leave out the critical immune and metabolic data that determine real outcomes. Using Envita’s comprehensive mapping, doctors can design custom therapies, including microdosed chemotherapy, precision drug combinations, and immunotherapy support, to target the cancer while protecting your immune system.
🎯 What You’ll Learn in This Episode:

• What Oncotype DX actually measures — and what it misses
• How the POETIC study measures hormone therapy response
• Why precision oncology provides a “full map” instead of a snapshot
• How immune profiling and spatial biology identify root causes
• How microdosed, targeted treatments reduce side effects
• Why adaptive monitoring helps prevent recurrence early

📊 Precision oncology brings together multi-omics testing and custom drug design to replace population-based care with truly personalized treatment planning.
“Your cancer is unique — your testing and treatment should be too.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493